Stable liposome aqueous suspension

• US 5,565,213 A
• Filed: 10/21/1994
• Issued: 10/15/1996
• Est. Priority Date: 07/26/1990
• Status: Expired due to Fees

• Current Assignee: Taisho Pharmaceutical Company Limited (Taisho Pharmaceutical Holdings Company Limited)
• Original Assignee: Taisho Pharmaceutical Company Limited (Taisho Pharmaceutical Holdings Company Limited)
• Inventors: Nakajima, Toshiaki, Koyama, Ikuo, Odawara, Mikiko, Yoshida, Tsuguchika, Nakamori, Katsu
• Primary Examiner(s): Kishore, Gollamudi S.
• Application Number:
  US08/318,750
• Time in Patent Office: 725 Days
• Field of Search: 424/450, 428/402.2
• US Class Current: 424/450
• CPC Class Codes: A61K 9/127 Liposomes
• CPC Class Codes: A61K 9/1272 with substantial amounts of non-phosphatidyl, i.e. non-acylglycerophosphate, surfactants as bilayer-forming substances, e.g. cationic lipids with cholesterol as the only non-phosphatidyl surfactant A61K9/127; lipids as modifying agent A61K47/543
• CPC Class Codes: B01J 13/0021 containing a solid organic phase
• CPC Class Codes: Y10T 428/2984 Microcapsule with fluid core [includes liposome]

Abstract

A liposome aqueous suspension containing taurine and benzalkonium chloride is disclosed. The liposome aqueous suspension undergoes no precipitation, agglomeration or change in particle size even when preserved at 40° C. for 6 months and is inhibited from lyso-phospholipid formation.

Claims

1. A liposome aqueous suspension containing taurine in the liposomes and the external aqueous phase, which contains 0.5 to 5.0% by weight of taurine based on the total amount of the liposome preparation and 0.05 to 20 mol %, based on the membrane component of the liposomes, of benzalkonium chloride in the membranes of the liposomes and the external aqueous phase.